Pfizer’s experimental weight loss drug, PF-08653944, demonstrated in a Phase 2b trial that patients lost up to 12.3% of their body weight after 28 weeks with monthly injections, matching the efficacy of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound whereas requiring far fewer doses.
This dosing advantage could disrupt a market where adherence remains a critical challenge. At least half of patients discontinue weekly GLP-1 therapies within a year, often citing cost and inconvenience. By cutting the injection frequency from roughly 52 doses annually to just 12, Pfizer’s approach may lower the total cost of treatment and improve long-term retention — a factor already eroding Novo Nordisk’s market position, as Wegovy prescriptions declined late in 2025 despite price cuts for self-pay users.
Pfizer’s monthly shot targets the core weakness in current obesity treatments
The primary barrier to sustained use of drugs like Wegovy and Zepbound isn’t efficacy — it’s the burden of weekly injections. Patients report injection fatigue, scheduling difficulties, and out-of-pocket expenses that accumulate over time. Pfizer’s PF-08653944, administered once a month, directly addresses this friction point. In the VESPER-3 trial, side effects were consistent with existing GLP-1 drugs — mostly mild or moderate gastrointestinal issues — with no more than one case of severe nausea or vomiting per dose group. Ten of 108 participants discontinued due to adverse events, a rate comparable to competitor trials.
Dr. Albert Bourla emphasized the drug’s competitive profile, telling CNBC that the data were “very good” and that the monthly regimen offers a compelling balance of tolerability and efficacy. Pfizer plans to advance a 9.6-milligram maintenance dose into Phase 3 based on these results. The drug originated from Metsera, a biotech Pfizer acquired in a bidding war with Novo Nordisk last year, underscoring the intensity of competition in this space.
Amgen and Eli Lilly are also advancing monthly alternatives, intensifying the race
Pfizer is not alone in pursuing less frequent dosing. Amgen’s MariTide, another monthly injectable, is already in multiple Phase 3 trials. Meanwhile, Eli Lilly is developing retatrutide, a triple-hormone agonist that in late-stage trials enabled patients to lose an average of up to 71.2 pounds over 68 weeks — far surpassing current GLP-1 monotherapies. Lilly is also exploring oral formulations and next-generation weekly shots, signaling that innovation extends beyond dosing frequency.
Novo Nordisk, too, is expanding its pipeline with oral semaglutide and other variants, attempting to defend its dominance as the market grows. Precedence Research projects the global anti-obesity drug market will expand at nearly 25% annually through 2035, attracting entrants eager to capture share in a sector projected to be worth hundreds of billions.
Novo Nordisk faces headwinds as patients shift between brands
Despite Wegovy’s early success, Novo Nordisk reported declining prescriptions toward the end of 2025, even after introducing a self-pay price reduction. The company now forecasts a 5% to 13% drag on both revenue and earnings this year due to weakening demand in its weight-loss segment. Some of that loss appears to be flowing to Zepbound, which saw revenue surge 175% from $4.9 billion to $13.5 billion in the prior year as patients switched or added Lilly’s drug to their regimen.
This churn reveals a market where loyalty is low and switching costs are minimal — especially when efficacy is comparable. A monthly option like PF-08653944 could accelerate this trend by offering a simpler, potentially cheaper alternative without sacrificing results.
How does Pfizer’s monthly dosing compare to current weight loss shots in terms of convenience and cost?
Pfizer’s drug requires only 12 injections per year versus approximately 52 for weekly Wegovy or Zepbound, reducing the burden of clinic visits or self-injection and potentially lowering annual out-of-pocket costs if pricing remains competitive.
What evidence suggests patients struggle with adherence to existing GLP-1 weight loss drugs?
At least half, and up to two-thirds, of users discontinue weekly GLP-1 therapies within a year, with cost and treatment fatigue frequently cited as reasons — a trend already reflected in declining Wegovy prescriptions despite price reductions in late 2025.
Is Pfizer’s drug as effective as Wegovy and Zepbound based on current trial data?
Yes — in the Phase 2b trial, PF-08653944 produced weight loss of 10% to 12% at 28 weeks, which aligns with the efficacy seen in approved weekly GLP-1 drugs, and showed no plateau, indicating further loss is likely with extended treatment.
